P16 as a molecular biomarker of cervical adenocarcinoma

John O. Schorge, Jayanthi S. Lea, Keren J. Elias, Ramababu Rajanbabu, Robert L. Coleman, David S. Miller, Raheela Ashfaq

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: Cervical adenocarcinomas are increasing in incidence each year. The aim of this study was to identify a molecular biomarker to improve early detection. Study design: Fifty-five in situ and invasive cervical adenocarcinomas were compared with 5 normal endocervical controls by immunohistochemical analysis of p16, p21, p27, cyclin D1, cyclin E, p53, and Ki-67. Expression was scored from 0 to 8 by using an automated imaging system. Western blotting and polymerase chain reaction-based human papillomavirus (HPV) testing were performed on 16 of the invasive cases having fresh-frozen tissue. Results: P16 exhibited a higher mean expression score for in situ (7.4; P < .0001) and invasive cervical adenocarcinoma (6.6; P < .0001) versus controls (2.0). A cutoff p16 expression score of 5 had a sensitivity of 94.5% and a specificity of 100%. Western blotting confirmed p16 protein expression. Fourteen (88%) of 16 invasive cervical adenocarcinomas were HPV-positive. Conclusion: P16 is a putative molecular biomarker of cervical adenocarcinoma. Overexpression appears to primarily reflect HPV-induced cell cycle dysregulation.

Original languageEnglish (US)
Pages (from-to)668-673
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume190
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Adenocarcinoma
Biomarkers
Western Blotting
Cyclin E
Cyclin D1
Cell Cycle
Polymerase Chain Reaction
Incidence
Proteins

Keywords

  • Adenocarcinoma in situ
  • Biomarker
  • Cervical adenocarcinoma
  • P16

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

P16 as a molecular biomarker of cervical adenocarcinoma. / Schorge, John O.; Lea, Jayanthi S.; Elias, Keren J.; Rajanbabu, Ramababu; Coleman, Robert L.; Miller, David S.; Ashfaq, Raheela.

In: American Journal of Obstetrics and Gynecology, Vol. 190, No. 3, 03.2004, p. 668-673.

Research output: Contribution to journalArticle

Schorge, John O. ; Lea, Jayanthi S. ; Elias, Keren J. ; Rajanbabu, Ramababu ; Coleman, Robert L. ; Miller, David S. ; Ashfaq, Raheela. / P16 as a molecular biomarker of cervical adenocarcinoma. In: American Journal of Obstetrics and Gynecology. 2004 ; Vol. 190, No. 3. pp. 668-673.
@article{76fd15681c684c8383fdc41fe860c68b,
title = "P16 as a molecular biomarker of cervical adenocarcinoma",
abstract = "Objective: Cervical adenocarcinomas are increasing in incidence each year. The aim of this study was to identify a molecular biomarker to improve early detection. Study design: Fifty-five in situ and invasive cervical adenocarcinomas were compared with 5 normal endocervical controls by immunohistochemical analysis of p16, p21, p27, cyclin D1, cyclin E, p53, and Ki-67. Expression was scored from 0 to 8 by using an automated imaging system. Western blotting and polymerase chain reaction-based human papillomavirus (HPV) testing were performed on 16 of the invasive cases having fresh-frozen tissue. Results: P16 exhibited a higher mean expression score for in situ (7.4; P < .0001) and invasive cervical adenocarcinoma (6.6; P < .0001) versus controls (2.0). A cutoff p16 expression score of 5 had a sensitivity of 94.5{\%} and a specificity of 100{\%}. Western blotting confirmed p16 protein expression. Fourteen (88{\%}) of 16 invasive cervical adenocarcinomas were HPV-positive. Conclusion: P16 is a putative molecular biomarker of cervical adenocarcinoma. Overexpression appears to primarily reflect HPV-induced cell cycle dysregulation.",
keywords = "Adenocarcinoma in situ, Biomarker, Cervical adenocarcinoma, P16",
author = "Schorge, {John O.} and Lea, {Jayanthi S.} and Elias, {Keren J.} and Ramababu Rajanbabu and Coleman, {Robert L.} and Miller, {David S.} and Raheela Ashfaq",
year = "2004",
month = "3",
doi = "10.1016/j.ajog.2003.09.038",
language = "English (US)",
volume = "190",
pages = "668--673",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - P16 as a molecular biomarker of cervical adenocarcinoma

AU - Schorge, John O.

AU - Lea, Jayanthi S.

AU - Elias, Keren J.

AU - Rajanbabu, Ramababu

AU - Coleman, Robert L.

AU - Miller, David S.

AU - Ashfaq, Raheela

PY - 2004/3

Y1 - 2004/3

N2 - Objective: Cervical adenocarcinomas are increasing in incidence each year. The aim of this study was to identify a molecular biomarker to improve early detection. Study design: Fifty-five in situ and invasive cervical adenocarcinomas were compared with 5 normal endocervical controls by immunohistochemical analysis of p16, p21, p27, cyclin D1, cyclin E, p53, and Ki-67. Expression was scored from 0 to 8 by using an automated imaging system. Western blotting and polymerase chain reaction-based human papillomavirus (HPV) testing were performed on 16 of the invasive cases having fresh-frozen tissue. Results: P16 exhibited a higher mean expression score for in situ (7.4; P < .0001) and invasive cervical adenocarcinoma (6.6; P < .0001) versus controls (2.0). A cutoff p16 expression score of 5 had a sensitivity of 94.5% and a specificity of 100%. Western blotting confirmed p16 protein expression. Fourteen (88%) of 16 invasive cervical adenocarcinomas were HPV-positive. Conclusion: P16 is a putative molecular biomarker of cervical adenocarcinoma. Overexpression appears to primarily reflect HPV-induced cell cycle dysregulation.

AB - Objective: Cervical adenocarcinomas are increasing in incidence each year. The aim of this study was to identify a molecular biomarker to improve early detection. Study design: Fifty-five in situ and invasive cervical adenocarcinomas were compared with 5 normal endocervical controls by immunohistochemical analysis of p16, p21, p27, cyclin D1, cyclin E, p53, and Ki-67. Expression was scored from 0 to 8 by using an automated imaging system. Western blotting and polymerase chain reaction-based human papillomavirus (HPV) testing were performed on 16 of the invasive cases having fresh-frozen tissue. Results: P16 exhibited a higher mean expression score for in situ (7.4; P < .0001) and invasive cervical adenocarcinoma (6.6; P < .0001) versus controls (2.0). A cutoff p16 expression score of 5 had a sensitivity of 94.5% and a specificity of 100%. Western blotting confirmed p16 protein expression. Fourteen (88%) of 16 invasive cervical adenocarcinomas were HPV-positive. Conclusion: P16 is a putative molecular biomarker of cervical adenocarcinoma. Overexpression appears to primarily reflect HPV-induced cell cycle dysregulation.

KW - Adenocarcinoma in situ

KW - Biomarker

KW - Cervical adenocarcinoma

KW - P16

UR - http://www.scopus.com/inward/record.url?scp=1642505577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642505577&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2003.09.038

DO - 10.1016/j.ajog.2003.09.038

M3 - Article

C2 - 15041997

AN - SCOPUS:1642505577

VL - 190

SP - 668

EP - 673

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -